FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CTATEMENT	OF CHANCES	IN DENECICIAL	OWNEDCLUD
STATEMENT	OF CHANGES	IN BENEFICIAL	OMNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average	burden							
hours per response	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wallace Owen B. (Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC.					3. C	2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC] 3. Date of Earliest Transaction (Month/Day/Year) 05/27/2020 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title Other (specify below) Chief Scientific Officer														
26 LANI (Street) CAMBR (City)		ÍA (02139 (Zip)		4. If	f Ame	endment	t, Date	of O	riginal F	iled	(Month/D	ay/Yea	ar)	Line	e) <mark>X</mark> Form	filed by One	e Repo	g (Check Ap orting Perso n One Repo	n
		Tahi	e I - Noi	n-Deriv	vative	Sec	curitie		nui	ired C	nei(nosed (of or	Ren	eficial	lly Owne	d			
Date		2. Trans	action	ction 2A. Deeme Execution ay/Year) if any		A. Deemed xecution Date,		3. 4. Sec Transaction Dispo Code (Instr. 5)		4. Secur Dispose	ities Ad	cquired	d (A) or	5. Amo Securit Benefic	unt of ies cially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									ſ	Code	v	Amount		(A) or (D)	Price	Transa	ed ction(s) 3 and 4)			(Instr. 4)
Common Stock 05/2			05/27	7/2020	2020			M ⁽¹⁾		448	448 A S		\$7.8	4 127,536			D			
Common Stock 05/2			05/27	7/2020	/2020				S ⁽¹⁾		448 D		\$20	127,088			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	te Execution		4. Transa Code (8)		n of E		Exp	6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exer	e rcisable		opiration		1	Amount or Number of Shares					
Stock Option (right to	\$7.84	05/27/2020			M ⁽¹⁾			448		(2)	01	/21/2029	Comm		448	\$0.00	87,266	5	D	

Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.
- 2. The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

Remarks:

/s/ Peter Thomson, as attorneyin-fact for Owen B. Wallace

05/29/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.